BERLIN–(DWPR)–TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for cancer treatment by targeting the tumor microenvironment (TME), announced the successful completion of its €2.6 million capital increase through a public offer reserved for shareholders as of December 11, 2024.

“We are pleased with the strong support from our shareholders, with over 77% participation in the offer,” said Aram Mangasarian, CEO of TME Pharma. “This financing enables us to advance strategic initiatives for NOX-A12 and NOX-E36, focusing on clinical development and licensing opportunities to create shareholder value.”

The capital increase, which led to the issuance of 52,000,000 new ordinary shares at €0.05 each, raised €2.6 million in gross proceeds. The funds will extend TME Pharma’s financial visibility into June 2025 and allow the company to complete the ongoing NOX-A12 GLORIA Phase 1/2 trial and pursue licensing agreements for both NOX-A12 and NOX-E36.

The transaction involved €2,015,549.10 subscribed by existing shareholders and €584,450.90 covered by guarantors. The new shares will be admitted to Euronext Growth Paris on December 27, 2024, under ISIN code NL0015000YE1.

Contacts

Aram Mangasarian, Ph.D.
CEO
[email protected]
Tel. +49 (0) 30 16637082 0

Guillaume van Renterghem
LifeSci Advisors
[email protected]
Tel. +41 (0) 76 735 01 31

Arthur Rouillé
NewCap
[email protected]
Tel. +33 (0) 1 44 71 00 15